Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.

Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE

Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute

Biomarkers/*blood ; Carcinoma, Non-Small-Cell Lung/*drug therapy ; Immune Checkpoint Inhibitors/*therapeutic use ; Inflammation/*blood ; Lung Neoplasms/*drug therapy; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Progression-Free Survival ; Retrospective Studies

Background: Inflammation-nutritional markers of peripheral blood are easily assessed and can predict survival. The aim of this study was to investigate the association between inflammation-nutritional parameters and survival of anti-programmed death-1 (PD-1) therapy in non-small-cell lung cancer (NSCLC) patients.
Methods: We performed a retrospective study from March 2017 to April 2020 in advanced NSCLC patients treated with PD-1 inhibitors. Univariable and multivariable analyses were conducted to evaluate the relationship between peripheral blood parameters (absolute lymphocyte count [ALC], absolute neutrophil count [ANC], absolute monocyte count [AMC], absolute eosinocyte count [AEC], lactic dehydrogenase [LDH], plasma-albumin [ALB], neutrophil/lymphocyte ratio [NLR], and platelet/lymphocyte ratio [PLR]) measured before therapy initiation and prognosis.
Results: Among 184 evaluable patients, 134 (72.8%) were male and the median age was 58 years (range 33-87) with 31 (16.8%) ≥70 years. An elevated ANC (≥7500/ul), NLR (≥5), and PLR (≥200) was significantly associated with worse objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), while increased ALC (≥1000/ul) and ALB (≥3.5 g/dl) could significantly improve survival in terms of ORR, PFS, and OS. In multivariate analyses, higher AEC (≥150/ul) and AMC (≥650/ul) could significantly decrease the risk of death (hazard ratio [HR] 0.363, 95% confidence interval [CI] 0.141-0.931, p = 0.035; HR 0.370, 95% CI 0.203-0.675, p = 0.001). A higher NLR and PLR, and lower ALB were independent predictors of poor prognosis for OS (HR 1.964, 95% CI 1.027-3.755, p = 0.041; HR 4.255, 95% CI 2.364-7.658, p = 0.000; HR 1.962, 95% CI 1.213-3.174, p = 0.006, respectively).
Conclusion: Our research illustrated that pretreatment AEC, AMC, ALB, NLR, and PLR are independent predictors for survival in advanced NSCLC patients treated with PD-1 inhibitors.
(© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)

Ann Oncol. 2013 Jun;24(6):1697-703. (PMID: 23439861)
J Thorac Oncol. 2016 Mar;11(3):300-11. (PMID: 26723244)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174)
N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
Nat Med. 2018 Sep;24(9):1441-1448. (PMID: 30082870)
Anticancer Res. 2017 Oct;37(10):5857-5862. (PMID: 28982912)
Clin Lung Cancer. 2019 May;20(3):208-214.e2. (PMID: 29803573)
J Cell Physiol. 2018 Oct;233(10):6337-6343. (PMID: 29672849)
Ther Adv Med Oncol. 2019 Apr 16;11:1758835919839928. (PMID: 31019571)
J Thorac Oncol. 2018 Jan;13(1):97-105. (PMID: 29170120)
Lung Cancer. 2020 Jul;145:18-26. (PMID: 32388276)
Immunol Rev. 2016 Sep;273(1):312-28. (PMID: 27558343)
J Natl Cancer Inst. 2014 May 29;106(6):dju124. (PMID: 24875653)
Nat Commun. 2017 Feb 01;8:14381. (PMID: 28146145)
J Clin Oncol. 2007 Apr 20;25(12):1562-9. (PMID: 17443000)
Eur J Cancer. 2018 Jan;89:56-63. (PMID: 29227818)
Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070)
JAMA Oncol. 2018 Mar 1;4(3):351-357. (PMID: 29327044)
Br J Cancer. 2011 Jun 28;105(1):93-103. (PMID: 21629244)
Clin Lung Cancer. 2018 Sep;19(5):426-434.e1. (PMID: 29803574)
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. (PMID: 27185375)
Thorac Cancer. 2021 Nov;12(21):2914-2923. (PMID: 34581010)
Nat Immunol. 2015 Jun;16(6):609-17. (PMID: 25915731)
Cancer Immunol Res. 2016 Feb;4(2):83-91. (PMID: 26839309)
Med Res Rev. 2011 May;31(3):311-63. (PMID: 19967776)
Ann Coloproctol. 2016 Dec;32(6):208-214. (PMID: 28119863)
Adv Ther. 2020 Mar;37(3):1145-1155. (PMID: 32002809)
Cancer Immunol Immunother. 2014 May;63(5):449-58. (PMID: 24609989)
Cancer. 2010 Apr 1;116(7):1767-75. (PMID: 20143434)
Lancet. 2017 Jan 21;389(10066):255-265. (PMID: 27979383)
Lung Cancer. 2017 Feb;104:1-6. (PMID: 28212990)
Ann Oncol. 2016 Apr;27(4):732-8. (PMID: 26802161)
Clin Cancer Res. 2015 Dec 15;21(24):5453-9. (PMID: 26289067)
Cancer Lett. 2019 Aug 10;457:168-179. (PMID: 31078738)
Br J Dermatol. 2016 Jan;174(1):146-51. (PMID: 26343230)
JAMA Oncol. 2016 Sep 1;2(9):1217-22. (PMID: 27310809)
J Thorac Dis. 2020 Apr;12(4):1520-1528. (PMID: 32395289)
Clin Cancer Res. 2016 Jun 15;22(12):2908-18. (PMID: 26787752)
Cancer Immunol Immunother. 2020 Sep;69(9):1813-1822. (PMID: 32350592)
Br J Cancer. 2016 Feb 2;114(3):256-61. (PMID: 26794281)
J Thorac Oncol. 2016 Jul;11(7):976-88. (PMID: 26944305)
Immunity. 2016 Jun 21;44(6):1255-69. (PMID: 27332730)
Clin Cancer Res. 2016 Oct 1;22(19):4848-4858. (PMID: 27169993)
Lung Cancer. 2017 Apr;106:1-7. (PMID: 28285682)
JAMA Oncol. 2019 Aug 1;5(8):1195-1204. (PMID: 31318407)

Keywords: PD-1 inhibitors; inflammation-nutritional markers; lung cancer; predictive parameters; survival

0 (Biomarkers)
0 (Immune Checkpoint Inhibitors)

Date Created: 20210928 Date Completed: 20220201 Latest Revision: 20220201

20231215

PMC8563162

10.1111/1759-7714.14152

34581010